Allosteric modulation of G protein-coupled receptors

Annual Review of Pharmacology and Toxicology

Volumn 47, Issue , 2007, Pages 1-51

  May, Lauren T ^a   Leach, Katie ^b   Sexton, Patrick M ^b   Christopoulos, Arthur ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Drug discovery; Efficacy; Receptor theory; Structural biology

Indexed keywords

1,6 HEXAMETHYLENEBIS[DIMETHYL(3 PHTHALIMIDOPROPYL)AMMONIUM BROMIDE]; 2 AMINO 3 (3,4 DICHLOROBENZOYL) 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; AC 42; ACETYLSALICYLIC ACID; ADENOSINE; ADRENERGIC RECEPTOR; AGMATINE; AK 530; AMILORIDE; AMN 082; APLAVIROC; BENZODIAZEPINE; CALCIUM SENSING RECEPTOR; CANNABINOID; CGP 13501; CGP 7930; CHEMOKINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; DOPAMINE; EGLUMETAD; ENDOTHELIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE; GLUCAGON RECEPTOR; GLUTAMATE RECEPTOR; GROWTH HORMONE; GS 39783; HEPARIN; LIGAND; LY 181837; MUSCARINIC RECEPTOR; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NBI 35965; NEUROKININ; OPIATE RECEPTOR; ORG 27569; ORG 27759; ORG 29647; PNU 69176E; PURINE RECEPTOR; RECEPTOR SUBTYPE; SCH 873140; SEROTONIN RECEPTOR; UCB 35625; UNCLASSIFIED DRUG; UNINDEXED DRUG; VU 5455; VU 8504; WIN 62577; ZINC;

ALLOSTERISM; BINDING SITE; CRYSTAL STRUCTURE; DESENSITIZATION; DISSOCIATION; DRUG RECEPTOR BINDING; HUMAN; LIGAND BINDING; MACROMOLECULE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RELIABILITY; REVIEW; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; DRUG DESIGN; LIGANDS; MODELS, MOLECULAR; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847122495     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.47.120505.105159     Document Type: Review

References (149)

1. Foord S. 2002. Receptor classification: post genome. Curr. Opin. Pharmacol. 2:561
2. Christopoulos A. 2002. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1:198-210
3. Bouvier M. 2001. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2:274-86
4. Brady AE, Limbird LE. 2002. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell Signal 14:297-309
5. Bohr C, Hasselbalch KA, Krogh A. 1904. Ubereinen in biologischen Beziehung wichtigen Einfluss, den die Kohlen-sauerspannungdes Blutes auf dessen Sauerstoffbindung ubt. Skand. Arch. Physiol. 16:402-12
6. Christopoulos A, Kenakin T. 2002. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54:323-74
7. Wyman J, Allen DW. 1951. The problem of heme interactions in hemoglobin and the basis for the Bohr effect. J. Polymer. Sci. 7:499-518
8. Katz B, Thesleff S. 1957. A study of the 'desensitization' produced by acetylcholine at the motor end-plate. J. Physiol. 138:63-80
9. Monod J, Changeux JP, Jacob F. 1963. Allosteric proteins and cellular control systems. J. Mol. Biol. 6:306-29
10. Monod J, Wyman J, Changeux JP. 1965. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12:88-118
11. Ehlert FJ. 1985. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol. 28:410-21
12. Neubig RR, Spedding M, Kenakin T, Christopoulos A. 2003. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 55:597-606
13. Kenakin T. 2005. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4:919-27
14. Lockless SW, Ranganathan R. 1999. Evolutionarily conserved pathways of energetic connectivity in protein families. Science 286:295-99
15. Hardy JA, Wells JA. 2004. Searching for new allosteric sites in enzymes. Curr. Opin. Struct. Biol. 14:706-15
16. Swain JF, Gierasch LM. 2006. The changing landscape of protein allostery. Curr. Opin. Struct. Biol. 16:102-8
17. Freire E. 2000. Can allosteric regulation be predicted from structure? Proc. Natl. Acad. Sci. USA 97:11680-82
18. Ehlert FJ. 1988. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33:187-94
19. Kenakin TP. 1997. Pharmacologic Analysis of Drug-Receptor Interaction. Philadelphia, PA: Lippincott-Raven
20. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, et al. 1999. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 55:453-61
21. Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, et al. 2001. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)- phenol(CGP7930) and its aldehyde analog CGP13501. Mol. Pharmacol. 60:963-71
22. Zahn K, Eckstein N, Trankle C, Sadee W, Mohr K. 2002. Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J. Pbarmacol. Exp. Ther. 301:720-28
23. Watson C, Jenkinson S, Kazmierski W, Kenakin T. 2005. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67:1268-82
24. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, et al. 2005. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 68:1484-95
25. Ehlert FJ. 2005. Analysis of allosterism in functional assays. J. Pharmacol. Exp. Ther. 315:740-54
26. Kenakin T. 2004. Allosteric modulators: the new generation of receptor antagonist. Mol. Interv. 4:222-29
27. Hall DA. 2000. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 58:1412-23
28. Bruns RF, Fergus JH. 1990. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38:939-49
29. Figler H, Olsson RA, Linden J. 2003. Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. Mol. Pharmacol. 64:1557-64
30. Sachpatzidis A, Benton BK, Manfredi JP, Wang H, Hamilton A, et al. 2003. Identification of allosteric peptide agonists of CXCR4. J. Biol. Cbem. 278:896-907
31. Binet V, Brajon C, Le Corre L, Acher F, Pin JP, Prezeau L. 2004. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J. Biol. Chem. 279:29085-91
32. Goudet C, Gaven F, Kniazeff J, Vol C, Liu J, et al. 2004. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc. Natl. Acad. Sci. USA 101:378-83
33. Mitsukawa K, Yamamoto R, Ofner S, NozulakJ, Pescott O, et al. 2005. A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc. Natl. Acad. Sci. USA 102:18712-17
34. Holst B, Brandt E, Bach A, Heding A, Schwartz TW. 2005. Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Mol. Endocrinol. 19:2400-11
35. Langmead CJ, Fry VA, Forbes IT, Branch CL, Christopoulos A, et al. 2006. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2- methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol. Pharmacol. 69:236-46
36. Holst B, Elling CE, Schwartz TW. 2002. Metal ion-mediated agonism and agonist enhancement in melanocortin MC1 and MC4 receptors. J. Biol. Chem. 277:47662-70
37. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, et al. 2005. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioural models. J. Pharmacol. Exp. Ther. 313:199-206
38. Schwartz TW, Holst B. 2006. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J. Recept. Signal Transduct. Res. 26:107-28
39. 2 dopamine receptors by amiloride and amiloride analogs. Mol. Pharmacol. 50:1295-308
40. 3H] scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol. Pharmacol. 58:194-207
41. Durroux T. 2005. Principles: a model for the allosteric interactions between ligancl binding sites within a dimeric GPCR. Trends Pharmacol. Sci. 26:376-84
42. Christopoulos A, Parsons AM, Lew MJ, El-Fakahany EE. 1999. The assessment of antagonist potency under conditions of transient response kinetics. Eur. J. Pharmacol. 382:217-27
43. Gao ZG, Van Muijlwijk-Koezen JE, Chen A, Muller CE, Ijzerman AP, Jacobson KA. 2001. Allosteric modulation of a(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol. Pharmacol. 60:1057-63
44. 4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 65:257-66
45. Portoghese PS. 1989. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 10:230-35
46. Disingrini T, Muth M, Dallanoce C, Barocelli E, Bertoni S, et al. 2006. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J. Med. Chem. 49:366-72
47. May LT, Avlani VA, Sexton PM, Christopoulos A. 2004. Allosteric modulation of G protein-coupled receptors. Curr. Pharm. Des. 10:2003-13
48. Klaasse EC, van den Hout G, Roerink SF, de Grip WJ, Ijzerman AP, Beukers MW. 2005. Allosteric modulators affect the internalization of human adenosine A(1) receptors. Eur. J. Pharmacol. 522:1-8
49. May LT, Lin Y, Sexton PM, Christopoulos A. 2005. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators. J. Pharmacol. Exp. Ther. 312:382-90
50. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, et al. 2002. Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol. Pharmacol. 61:1297-302
51. Motulsky HJ, Mahan LC. 1984. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25:1-9
52. Lazareno S, Birdsall NJM. 1995. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48:362-78
53. Kostenis E, Mohr K. 1996. Composite action of allosteric modulators on ligand binding. Trends Pharmacol. Sci. 17:443-44
54. Avlani VA, May LT, Sexton PM, Christopoulos A. 2004. Application of a kinetic model to the apparently complex behaviors of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 308:1062-72
55. Lanzafame AA, Guida E, Christopoulos A. 2004. Effects of anandamide on the binding and signaling properties of M1 muscarinic acetylcholine receptors. Biochem. Pharmacol. 68:2207-19
56. 1 muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 308:830-37
57. Lazareno S, Popham A, Birdsall NJ. 2002. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol. Pharmacol. 62:1492-505
58. Ellis J, Seidenberg M. 1992. Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol. Pharmacol. 42:638-41
59. Rees S, Morrow D, Kenakin T. 2002. GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 8:261-68
60. 2 muscarine receptors. Mol. Pharmacol. 46:105-14
61. Christopoulos A, Mitchelson F. 1997. Application of an allosteric ternary complex model to the technique of pharmacological resultant analysis. J. Pharm. Pharmacol. 49:781-86
62. Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, et al. 2003. N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J. Pharmacol. Exp. Ther. 307:322-30
63. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, et al. 2000. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-45
64. Cavasotto CN, Orry AJ, Abagyan RA. 2003. Structure-based identification of binding sites, native ligands and potential inhibitors for G-protein coupled receptors. Proteins 51:423-33
65. An J, Totrov M, Abagyan R. 2005. Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol. Cell Proteomics 4:752-61
66. Chen J, Hage DS. 2004. Quantitative analysis of allosteric drug-protein binding by biointeraction chromatography. Nat. Biotechnol. 22:1445-48
67. Annis DA, Nazef N, Chuang CC, Scott MP, Nash HM. 2004. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. Am. Chem. Soc. 126:15495-503
68. Mandell AJ, Selz KA, Owens MJ, Kinkead B, Shlesinger MF, et al. 2003. Cellular and behavioural effects of D2 dopamine receptor hydrophobic eigenmode-targeted peptide ligands. Neuropsychopharmacology 28:S98-107
69. Selz KA, Mandell AJ, Shlesinger MF, Arcuragi V, Owens MJ. 2004. Designing human M1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulators. Biophys. J. 86:1308-31
70. Christopoulos A, Lanzafame A, Mitchelson F. 1998. Allosteric interactions at muscarinic cholinoceptors. Clin. Exp. Pharmacol. Physiol. 25:184-94
71. Leppik RA, Miller RC, Eck M, Paquet JL. 1994. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the M2 muscarinic acetylcholine receptor. Mol. Pharmacol. 45:983-90
72. Gnagey AL, Seidenberg M, Ellis J. 1999. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. Mol. Pharmacol. 56:1245-53
73. Krejci A, Tucek S. 2001. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Mol. Pharmacol. 60:761-67
74. Buller S, Zlotos DP, Mohr K, Ellis J. 2002. Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. Mol. Pharmacol. 61:160-68
75. Voigtlander U, Johren K, Mohr M, Raasch A, Tranlde C, et al. 2003. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol. Pharmacol. 64:21-31
76. Huang XP, Prilla S, Mohr K, Ellis J. 2005. Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3- phthalimidopropyl)ammonium]dibromide. Mol. Pharmacol. 68:769-78
77. Matsui H, Lazareno S, Birdsall NJ. 1995. Probing of the location of the allosteric site on M1 muscarinic receptors by site-directed mutagenesis. Mol. Pharmacol. 47:88-98
78. Prilla S, Schrobang J, Ellis J, Holtje HD, Mohr K. 2006. Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol. Pharmacol. 70:181-93
79. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, et al. 2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. USA 97:5639-44
80. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, et al. 2003. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77:5201-8
81. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, et al. 2006. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281(18):12688-98
82. Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, et al. 2006. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349(1):41-54
83. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, et al. 2004. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol 78:8654-62
84. De Clercq E. 2003. The bicyclam AMD3100 story. Nat. Rev. Drug Discov. 2:581-87
85. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW. 2001. Molecular interactions of cyclam and bicyclam nonpeptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 276:14153-60
86. Hatse S, Princen K, Gerlach LO, Bridger G, Henson G, et al. 2001. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol. Pharmacol. 60:164-73
87. Rosenkilde MM, Gerlach LO, Jakobsen JS, Skerlj RT, Bridger GJ, Schwartz TW. 2004. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J. Biol. Chem. 279:3033-41
88. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, et al. 1998. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J. Virol 72:6381-88
89. Kourounakis A, Visser C, de Groote M, IJzerman AP. 2001. Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3- trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. Biochem. Pharmacol. 61:137-44
90. Gao ZG, Kim SK, Gross AS, Chen A, Blaustein JB, Jacobson KA. 2003. Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. Mol. Pharmacol. 63:1021-31
91. Hoare SR. 2005. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov. Today 10:417-27
92. Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA. 1997. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol. Endocrinol. 11:2048-53
93. Hoare SR, Sullivan SK, Ling N, Crowe PD, Grigoriadis DE. 2003. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol. Pharmacol. 63:751-65
94. Cascieri MA, Koch GE, Ber E, Sadowski SJ, Louizides D, et al. 1999. Characterization of a novel, nonpeptidyl antagonist of the human glucagon receptor. J. Biol. Chem. 274:8694-97
95. Hay DL, Poyner DR, Sexton PM. 2006. GPCR modulation by RAMPs. Pharmacol. Ther. 109:173-97
96. Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, et al. 2002. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J. Biol. Chem. 277:14294-98
97. Pin JP, Kniazeff J, Liu J, Binet V, Goudet C, et al. 2005. Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J. 272:2947-55
98. Malherbe P, Kratochwil N, Knoflach F, Zenner MT, Kew JN, et al. 2003. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J. Biol. Chem. 278:8340-47
99. Lavreysen H, Janssen C, Bischoff F, Langlois X, Leysen JE, Lesage AS. 2003. [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol. Pharmacol. 63:1082-93
100. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, et al. 2000. The noncompetitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group 1 metabotropic glutamate receptors. J. Biol. Chem. 275:33750-58
101. Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, et al. 2001. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc. Natl. Acad. Sci. USA 98:13402-7
102. Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, et al. 2006. A novel class of positive allosteric modulators of mGluR1 interact with a site distinct from that of negative allosteric modulators. Mol. Pharmacol. 70(2):616-26
103. Baez M, Yang P, Kandasamy R, Large T, Kelly G, et al. 2002. Molecular mapping of a subtype selective site for positive allosteric modulation of the mGlu2 receptor. Neuropharmacology 43:275
104. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, et al. 2006. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. In press
105. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, et al. 2003. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 64:798-810
106. Muhlemann A, Ward NA, Kratochwil N, Diener C, Fischer C, et al. 2006. Determination of key amino acids implicated in the actions of allosteric modulation by 3,3′-difluorobenzaldazine on rat mGlu5 receptors. Eur. J. Pharmacol. 529:95-104
107. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, et al. 1998. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. USA 95:4040-45
108. 2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 299:323-31
109. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol. Pharmacol. 53:1083-88
110. Petrel C, Kessler A, Maslah F, Dauban P, Dodd RH, et al. 2003. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J. Biol. Chem. 278:49487-94
111. Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. 2004. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 279:7254-63
112. 2+ and a positive allosteric modulator. J. Biol. Chem. 277:46622-31
113. Urwyler S, Gjoni T, Kaupmann K, Pozza MF, Mosbacher J. 2004. Selected amino acids, dipeptides and arylalkylamine derivatives do not act as allosteric modulators at GABAB receptors. Eur. J. Pharmacol. 483:147-53
114. Mesnier D, Baneres JL. 2004. Cooperative conformational changes in a G-protein-coupled receptor dimer, the leukotriene B(4) receptor BLT1. J. Biol. Chem. 279:49664-70
115. Urizar E, Montanelli L, Loy T, Bonomi M, Swillens S, et al. 2005. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J. 24:1954-64
116. Springael JY, Le Minh PN, Urizar E, Costagliola S, Vassart G, Parmentier M. 2006. Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol. Pharmacol. 69:1652-61
117. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, et al. 2002. Inhibition of p38 MAP ldnase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9:268-72
118. Trankle C, Dittmann A, Schulz U, Weyand O, Buller S, et al. 2005. Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors. Mol. Pharmacol. 68:1597-610
119. 2+-binding site on the dopamine D2 receptor. Biochem. Biophys. Res. Commun. 339:873-79
120. Schetz JA, Sibley DR. 1997. Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. J. Neurochem. 68:1990-97
121. Schetz JA, Sibley DR. 2001. The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. J. Pharmacol. Exp. Ther. 296:359-63
122. 2+ on the beta2 adrenergic receptor. J. Biol. Chem. 278:352-56
123. Fowler CB, Pogozheva ID, LeVine H, Mosberg HI. 2004. Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. Biochemistry 43:8700-10
124. Costa T, Ogino Y, Munson PJ, Onaran HO, Rodbard D. 1992. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol. 41:549-60
125. Galvez T, Urwyler S, Prezeau L, Mosbacher J, JoIy C, et al. 2000. Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. Mol. Pharmacol. 57:419-26
126. 2+-sensing receptor. Proc. Natl. Acad. Sci. USA 97:4814-49
127. Massot O, Rousselle JC, Pillion MP, Grimaldi B, Cloez-Tayarani I, et al. 1996. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5- hydroxytryptamine1B/1D receptors. Mol. Pharmacol. 50:752-62
128. Massot O, Rousselle JC, Grimaldi B, Cloez-Tayarani I, Pillion MP, et al. 1998. Molecular, cellular and physiological characteristics of 5-HT-moduline, a novel endogenous modulator of 5-HT1B receptor subtype. Ann. N.Y. Acad. Sci. 861:174-82
129. Mishra RK, Makman MH, Costain WJ, Nair VD, Johnson RL. 1999. Modulation of agonist stimulated adenylyl cyclase and GTPase activity by L-proL-leu-glycinamide and its peptidomimetic analogue in rat striatal membranes. Neurosci. Lett. 269:21-24
130. Verma V, Mann A, Costain W, Pontoriero G, Castellano JM, et al. 2005. Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog. J. Pharmacol. Exp. Ther. 315:1228-36
131. Fryer AD, Jacoby DB. 1992. Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate. J. Clin. Invest. 90:2292-98
132. Hedlund PB, Carson MJ, Sutcliffe JG, Thomas EA. 1999. Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem. Pharmacol. 58:1807-13
133. Thomas EA, Carson MJ, Neal MJ, Sutcliffe JG. 1997. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc. Natl. Acad. Sci. USA 94:14115-19
134. Grazzini E, Guillon G, Mouillac B, Zingg HH. 1998. Inhibition of oxytocin receptor function by direct binding of progesterone. Nature 392:509-12
135. Gimpl G, Burger K, Fahrenholz F. 1997. Cholesterol as modulator of receptor function. Biochemistry 36:10959-74
136. Politowska E, Kazmierkiewicz R, Wiegand V, Fahrenholz F, Ciarkowski J. 2001. Molecular modelling study of the role of cholesterol in the stimulation of the oxytocin receptor. Acta Biochim. Pol. 48:83-93
137. Borda E, Pascual J, Cossio P, De La Vega M, Arana R, Sterin-Borda L. 1984. A circulating IgG in Chagas' disease which binds to beta-adrenoceptors of myocardium and modulates their activity. Clin. Exp. Immunol. 57:679-86
138. Goin JC, Borda E, Segovia A, Sterin-Borda L. 1991. Distribution of antibodies against beta-adrenoceptors in the course of human Trypanosoma cruzi infection. Proc. Soc. Exp. Biol. Med. 197:186-92
139. Goin JC, Leiros CP, Borda E, Sterin-Borda L. 1997. Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J. 11:77-83
140. Borda E, Camusso JJ, Perez Leiros C, Bacman S, Hubscher O, et al. 1996. Circulating antibodies against neonatal cardiac muscarinic acetylcholine receptor in patients with Sjogren's syndrome. Mol. Cell Biochem. 163-164:335-41
141. Bacman SR, Berra A, Sterin-Borda L, Borda ES. 1998. Human primary Sjogren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr. Eye Res. 17:1135-42
142. Ganzinelli S, Borda T, Sterin-Borda L. 2006. Regulation of m1 muscarinic receptors and nNOS mRNA levels by autoantibodies from schizophrenic patients. Neuropharmacology 50:362-71
143. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, et al. 1999. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 103:945-52
144. Elies R, Fu LX, Eftekhari P, Wallukat G, Schulze W, et al. 1998. Immunochemical and functional characterization of an agonist-like monoclonal antibody against the M2 acetylcholine receptor. Eur. J. Biochem. 251:659-66
145. Mobini R, Magnusson Y, Wallukat G, Viguier M, Hjalmarson A, Hoebeke J. 1999. Probing the immunological properties of the extracellular domains of the human beta(1)-adrenoceptor. J. Autoimmun. 13:179-86
146. Peter JC, Eftekhari P, Billiald P, Wallukat G, Hoebeke J. 2003. scFvsingle chain antibody variable fragment as inverse agonist of the beta2-adrenergic receptor. J. Biol. Chem. 278:36740-47
147. Peter JC, Wallukat G, Tugler J, Maurice D, Roegel JC, et al. 2004. Modulation of the M2 muscarinic acetylcholine receptor activity with monoclonal anti-M2 receptor antibody fragments. J. Biol. Chem. 279:55697-706
148. Bozon V, Di Scala E, Eftekhari P, Hoebeke J, Lezoualc'h F, et al. 2002. Agonist-like activity of antibodies directed against the second extracellular loop of the human cardiac serotonin 5-HT4(e) receptor in transfected COS-7 cells. Receptors Channels 8:113-21
149. Verdot L, Bertin B, Guilloteau D, Strosberg AD, Hoebeke J. 1995. Characterization of pharmacologically active antipeptide antibodies directed against the first and second extracellular loops of the serotonin 5-HT1A receptor. J. Neurochem. 65:319-28